Skip to main content
SpringerLink
Log in

Speedy/RINGO protein interacts with ERK/MAPK and PI3K/AKT pathways in SH-SY5Y neuroblastoma cells

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Abnormal activity of ERK/MAPK and PI3K/AKT pathways is one of the most important factors for the development of many cancer types including neuroblastoma cancer. Apart from these two pathways, some cell cycle regulators such as Speedy/RINGO also contribute to neuroblastoma development. There is data reinforcing the possible communication of the components of ERK/MAPK and PI3K/AKT pathways in carcinogenic process. In addition to this, there are studies about the direct/indirect interaction of Speedy/RINGO with these pathways in different cell types other than neuroblastoma. However, there is not any study available showing the interaction of Speedy/RINGO with both pathways in neuroblastoma cells. Therefore, the aim of this study is to determine the possible effect of Speedy/RINGO on PI3K/AKT and ERK/MAPK pathways in SH-SY5Y neuroblastoma cells. For this aim, Speedy/RINGO was silenced by siRNA technique to analyze the effects of direct inhibition of Speedy/RINGO on these pathways. Results showed that Speedy/RINGO silencing caused a significant decrease in MEK1/2 expression and AKT phosphorylation. Afterward, MEK1/2 was inhibited using a specific inhibitor U0126. Data reveal a corresponding decrease in the Speedy/RINGO expression and AKT phosphorylation indicating a reciprocal interaction between ERK/MAPK and Speedy/RINGO. In addition, MTS analysis showed that both ERK/MAPK inhibition and Speedy/RINGO silencing significantly reduced the viability of SH-SY5Y cells. This study provides information about a possible interaction of Speedy/RINGO with PI3K/AKT and ERK/MAPK pathways in SH-SY5Y cells for the first time. It will not only help to better understand the cancer-prone interactions of these pathways but also enable us to identify the appropriate molecular targets for developing efficient treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The authors confirm that the data supporting the findings of this study are available within the article.

Code availability

In this study, no content that will require code availability.

References

  1. Park JR, Eggert A, Caron H (2010) Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 24(1):65–86. https://doi.org/10.1016/j.hoc.2009.11.011

    Article  PubMed  Google Scholar 

  2. Kaneko Y, Kanda N, Maseki N, Sakurai M, Tsuchida Y, Takeda T, Okabe I, Sakurai M (1987) Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 47(1):311–318

    CAS  PubMed  Google Scholar 

  3. Tanaka T, Slamon DJ, Shimoda H, Waki C, Kawaguchi Y, Tanaka Y, Ida N (1988) Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient’s prognosis. Cancer Res 48(4):1030–1034

    CAS  PubMed  Google Scholar 

  4. Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M et al (2015) Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet 47:864–871. https://doi.org/10.1038/ng.3333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Johnsen JI, Segerström L, Orrego A, Elfman L, Henriksson M, Kågedal B, Eksborg S, Sveinbjörnsson B, Kogner P (2008) Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27:2910–2922. https://doi.org/10.1038/sj.onc.1210938

    Article  CAS  PubMed  Google Scholar 

  6. Wada T, Penninger JM (2004) Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23:2838–2849. https://doi.org/10.1038/sj.onc.1207556

    Article  CAS  PubMed  Google Scholar 

  7. Xu N, Lao Y, Zhang Y, Gillespie DA (2012) Akt: a double-edged sword in cell proliferation and genome stability. J Oncol 2012:15. https://doi.org/10.1155/2012/951724

    Article  CAS  Google Scholar 

  8. Porta C, Paglino C, Mosca A (2014) Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 4:64. https://doi.org/10.3389/fonc.2014.00064

    Article  PubMed  PubMed Central  Google Scholar 

  9. Opel D, Poremba C, Simon T, Debatin KM, Fulda S (2007) Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 67(2):735–745. https://doi.org/10.1158/0008-5472.CAN-06-2201

    Article  CAS  PubMed  Google Scholar 

  10. Li Z, Thiele CJ (2007) Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brainn-derived neurotrophic factor/TrkB signal transduction pathway. Expert Opin Ther Targets 11:1611–1621. https://doi.org/10.1517/14728222.11.12.1611

    Article  CAS  PubMed  Google Scholar 

  11. Boller D, Schramm A, Doepfner KT, Shalaby T, Von Bueren AO, Eggert A, Grotzer MA, Arcaro A (2008) Targeting the phosphoinositide 3-kinase isoform p110δ impairs growth and survival in neuroblastoma cells. Clin Cancer Res 14(4):1172–1181. https://doi.org/10.1158/1078-0432.CCR-07-0737

    Article  CAS  PubMed  Google Scholar 

  12. Paz-Ares L, Blanco-Aparicio C, García-Carbonero R, Carnero A (2009) Inhibiting PI3K as a therapeutic strategy against cancer. Clin Transl Oncol 11(9):572–579. https://doi.org/10.1007/s12094-009-0407-x

    Article  CAS  PubMed  Google Scholar 

  13. Kolch W (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351:289–305. https://doi.org/10.1042/0264-6021:3510289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Simon C, Hicks MJ, Nemechek AJ, Mehta R, O’Malley BW, Goepfert H, Flaitz CM, Boyd D (1999) PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Br J Cancer 80(9):1412–1419. https://doi.org/10.1038/sj.bjc.6690537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mattingly RR, Milstein ML, Mirkin BL (2001) Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells. Cell Signal 13(7):499–505. https://doi.org/10.1016/s0898-6568(01)00173-5

    Article  CAS  PubMed  Google Scholar 

  16. Aksamitiene E, Kiyatkin A, Kholodenko BN (2012) Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Tran 40(1):139–146. https://doi.org/10.1042/BST20110609

    Article  CAS  Google Scholar 

  17. Lubanska D, Porter LA (2014) The atypical cell cycle regulator Spy1 suppresses differentiation of the neuroblastoma stem cell population. Oncoscience 1(5):336–348. https://doi.org/10.18632/oncoscience.36

    Article  PubMed  PubMed Central  Google Scholar 

  18. Chauhan S, Zheng X, Tan YY, Tay BH, Lim S, Venkatesh B, Kaldis P (2012) Evolution of the Cdk-activator Speedy/RINGO in vertebrates. Cell Mol Life Sci 69(22):3835–3850. https://doi.org/10.1007/s00018-012-1050-1

    Article  CAS  PubMed  Google Scholar 

  19. Matsuo T, Seth P, Thiele CJ (2001) Increased expression of p27Kip1 arrests neuroblastoma cell growth. Med Pediatr Oncol 36(1):97–99. https://doi.org/10.1002/1096-911X(20010101)36:1<97:AID-MPO1022>3.0.CO;2-X

    Article  CAS  PubMed  Google Scholar 

  20. Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN (2009) Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Nati Acad Sci USA 106(31):12968–12973. https://doi.org/10.1073/pnas.0901418106

    Article  Google Scholar 

  21. Golipour A, Myers D, Seagroves T, Murphy D, Evan GI, Donoghue DJ, Moorehead RA, Porter LA (2008) The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Res 68(10):3591–3600. https://doi.org/10.1158/0008-5472.CAN-07-6453

    Article  CAS  PubMed  Google Scholar 

  22. Liu ML, Cheng YM, Jia MC (2010) LM23 is essential for spermatogenesis in Rattus norvegicus. Front Biosci (Elite Ed) 1(2):187–194. https://doi.org/10.2741/e81

    Article  Google Scholar 

  23. Pengda L, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, Tsou P, Gan W, Papa A, Kim BM, Wan L, Singh A, Zhai B, Yuan M, Wang Z, Gygi SP, Lee TH, Lu KP, Toker A, Pandolfi PP, Asara JM, Kirschner MW, Sicinski P, Cantley L, Wei W (2014) Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature 508(7497):541–545. https://doi.org/10.1038/nature13079

    Article  CAS  Google Scholar 

  24. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV (2019) STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47(D1):D607–D613. https://doi.org/10.1093/nar/gky1131

    Article  CAS  Google Scholar 

  25. McAndrew CW, Gastwirt RF, Donoghue DJ (2009) The atypical CDK activator Spy1 regulates the intrinsic DNA damage response and is dependent upon p53 to inhibit apoptosis. Cell Cycle 8(1):66–75. https://doi.org/10.4161/cc.8.1.7451

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Porter LA, Dellinger RW, Tynan JA, Barnes EA, Kong M, Lenormand JL, Donoghue DJ (2002) Human Speedy: a novel cell cycle regulator that enhances proliferation through activation of Cdk2. J Cell Biol 157(3):357–366. https://doi.org/10.1083/jcb.200109045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Morris MC, Gondeau C, Tainer JA, Divita G (2002) Kinetic mechanism of activation of the Cdk2/cyclin A complex: key role of the C-lobe of the Cdk. J Biol Chem 277(26):23847–23853. https://doi.org/10.1074/jbc.M107890200

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by grant to Aysegul Yildiz from Mugla Sitki Kocman University Scientific Research Project Office, Research and Development Projects (Project Numbers: 17/251 and 17/023). We sincerely thank Prof. Dr. Uygar Halis Tazebay from Gebze Technical University, Department of Molecular Biology and Genetics and Prof. Dr. Arzu Karabay Korkmaz from lstanbul Technical University, Faculty of Science and Letters, Molecular Biology and Genetics Department for allowing us to use their laboratory infrastructure. We would also thank Assoc. Prof. Emin Ilker Medine from Ege University Institute of Nuclear Sciences for his help about providing SH-SY5Y neuroblastoma cell line.

Funding

This study was funded by grants from the Scientific Research Project Office of Mugla Sitki Kocman University (Project Numbers: 17/251 and 17/023).

Author information

Authors and Affiliations

  1. Department of Molecular Biology and Genetics, Faculty of Science, Mugla Sitki Kocman University, Mugla, Turkey

    Yesim Kaya, Seren Kucukvardar & Aysegul Yildiz

  2. Department of Molecular Biology-Genetics and Biotechnology, Faculty of Science and Letters, Istanbul Technical University, Istanbul, Turkey

    Seren Kucukvardar

Authors
  1. Yesim Kaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seren Kucukvardar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aysegul Yildiz
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by [AY], [YK] and [SK]. The first draft of the manuscript was written by [AY] and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Aysegul Yildiz.

Ethics declarations

Conflicts of interest

The authors declare that they there are no competing interests.

Ethical approval

Ethic approval is not required for this study.

Consent to participate

In this study, no content that will require consent to participate.

Consent for publication

In this study, no content that will require consent for publication.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kaya, Y., Kucukvardar, S. & Yildiz, A. Speedy/RINGO protein interacts with ERK/MAPK and PI3K/AKT pathways in SH-SY5Y neuroblastoma cells. Mol Cell Biochem 473, 133–141 (2020). https://doi.org/10.1007/s11010-020-03813-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-020-03813-8

Keywords

Search

Navigation